Dulaglutide Subcutaneous and Lithium Carbonate
Determining the interaction of Dulaglutide Subcutaneous and Lithium Carbonate and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Lithium may occasionally affect blood glucose levels. Both hyperglycemia (high blood sugar) and, less frequently, hypoglycemia (low blood sugar) have been reported. Your blood glucose should be closely monitored during treatment with lithium so that your diabetic regimen may be adjusted, if needed. Let your doctor know if you experience hyperglycemia or hypoglycemia, or if you notice a loss of blood glucose control. Symptoms of hyperglycemia may include increased thirst, increased hunger, and increased urination. Symptoms of hypoglycemia include headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, perspiration, palpitation, and rapid heartbeat. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Lithium may interfere with the therapeutic effects of insulin and other antidiabetic agents. In one study, 10 psychiatric patients treated with lithium carbonate for two weeks demonstrated elevated blood glucose levels and impaired glucose tolerance tests. There have also been isolated case reports of hyperglycemia, impaired glucose tolerance, or diabetes mellitus in patients receiving lithium therapy, although a causal relationship has not been established. According to the labeling for several insulin products, lithium can either potentiate or weaken the blood glucose-lowering effect of insulin. The mechanism by which lithium may induce these changes is not understood.
MANAGEMENT: Blood glucose should be monitored more closely following initiation or discontinuation of lithium in patients receiving insulin or other antidiabetic agents. If hypo- or hyperglycemia occur during lithium therapy, patients should initiate appropriate remedial therapy immediately and contact their physician. Dosage adjustments may be required if an interaction is suspected.
- "Product Information. Lantus (insulin glargine)" Aventis Pharmaceuticals, Swiftwater, PA.
- "Product Information. NovoLog Mix 70/30 FlexPen (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
- "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.
- Shopsin B, Stern S, Gershon S "Altered carbohydrate metabolism during treatment with lithium carbonate." Arch Gen Psychiatry 26 (1972): 566-71
Generic Name: dulaglutide
Brand name: Trulicity Pen, Trulicity
Synonyms: Dulaglutide
Generic Name: lithium
Brand name: Lithobid, Eskalith, Lithonate, Lithotabs, Eskalith-CR
Synonyms: Lithium
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dulaglutide Subcutaneous-Lithium Carbonate ER Tablets
- Dulaglutide Subcutaneous-Lithium Carbonate Tablets
- Dulaglutide Subcutaneous-Lithium Citrate Syrup
- Dulaglutide Subcutaneous-Lithium Controlled-Release and Extended-Release Tablets
- Dulaglutide Subcutaneous-Lithium ER
- Dulaglutide Subcutaneous-Lithium Oral Solution
- Lithium Carbonate-Dulcolax
- Lithium Carbonate-Dulcolax (Bisacodyl Suppositories)
- Lithium Carbonate-Dulcolax (Bisacodyl Tablets)
- Lithium Carbonate-Dulcolax Milk of Magnesia
- Lithium Carbonate-Dulcolax Stool Softener
- Lithium Carbonate-Dulcolax Suppository